{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:54:44Z","timestamp":1785214484009,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek Vlaanderen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejpb.2024.114223","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T10:40:08Z","timestamp":1707993608000},"page":"114223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evaluating \u03b22-agonists as siRNA delivery adjuvants for pulmonary surfactant-coated nanogel inhalation therapy"],"prefix":"10.1016","volume":"197","author":[{"given":"Pieterjan","family":"Merckx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet","family":"Conickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5079-0675","authenticated-orcid":false,"given":"Evy","family":"Blomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-6928","authenticated-orcid":false,"given":"Tania","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-4605","authenticated-orcid":false,"given":"Ken R.","family":"Bracke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-8505","authenticated-orcid":false,"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan C.","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-4715","authenticated-orcid":false,"given":"Koen","family":"Raemdonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114223_b0005","unstructured":"WHO - The top 10 causes of death, (n.d.). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (accessed July 2, 2019)."},{"key":"10.1016\/j.ejpb.2024.114223_b0010","unstructured":"Forum of International Respiratory Societies. The Global Impact of Respiratory Disease \u2013 Second Edition, 2017."},{"key":"10.1016\/j.ejpb.2024.114223_b0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejpb.2024.114223_b0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.drudis.2008.06.008","article-title":"Maintaining the silence: reflections on long-term RNAi","volume":"13","author":"Raemdonck","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2024.114223_b0025","doi-asserted-by":"crossref","unstructured":"R. Kandil, O.M. Merkel, Pulmonary delivery of siRNA as a novel treatment for lung diseases, 10 (2019) 203\u2013206. Doi: 10.4155\/tde-2019-0009.","DOI":"10.4155\/tde-2019-0009"},{"key":"10.1016\/j.ejpb.2024.114223_b0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114223_b0035","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejpb.2024.114223_b0040","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jconrel.2020.11.005","article-title":"Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges","volume":"330","author":"Ding","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2021.11.023","article-title":"Pulmonary surfactant as a versatile biomaterial to fight COVID-19","volume":"342","author":"Herman","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2019.08.004","article-title":"Brief update on endocytosis of nanomedicines","volume":"144","author":"Patel","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114223_b0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114223_b0065","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114223_b0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114223_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114041","article-title":"Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics","volume":"181","author":"Van de Vyver","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114223_b0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2024.114223_b0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2015.03.015","article-title":"Bio-inspired pulmonary surfactant-modified nanogels: a promising siRNA delivery system","volume":"206","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jconrel.2015.08.030","article-title":"Hybrid pulmonary surfactant-coated nanogels mediate efficient in vivo delivery of siRNA to murine alveolar macrophages","volume":"217","author":"De Backer","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejpb.2020.09.011","article-title":"Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy","volume":"157","author":"Merckx","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114223_b0100","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/adfm.200801795","article-title":"Biodegradable dextran nanogels for RNA interference: focusing on endosomal escape and intracellular siRNA delivery","volume":"19","author":"Raemdonck","year":"2009","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejpb.2024.114223_b0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.actbio.2018.08.012","article-title":"Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy","volume":"78","author":"Merckx","year":"2018","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejpb.2024.114223_b0110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2018.10.012","article-title":"Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins","volume":"291","author":"Guagliardo","year":"2018","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.ejpb.2024.114223_b0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/pharmaceutics11090431","article-title":"Nanocarrier lipid composition modulates the impact of pulmonary surfactant protein B (SP-B) on cellular delivery of siRNA","volume":"11","author":"Guagliardo","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114223_b0120","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1021\/acsnano.0c04489","article-title":"Surfactant Protein B promotes cytosolic SiRNA delivery by adopting a virus-like mechanism of action","volume":"15","author":"Guagliardo","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2024.114223_b0125","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jconrel.2017.11.019","article-title":"Repurposing cationic amphiphilic drugs as adjuvants to induce lysosomal siRNA escape in nanogel transfected cells","volume":"269","author":"Joris","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0130","doi-asserted-by":"crossref","first-page":"44277","DOI":"10.1038\/srep44277","article-title":"New insights into the intracellular distribution pattern of cationic amphiphilic drugs","volume":"7","author":"Vater","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2024.114223_b0135","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/nar\/gkx1320","article-title":"Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides","volume":"46","author":"Juliano","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejpb.2024.114223_b0140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1042\/BST20140145","article-title":"Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death","volume":"42","author":"Villamil Giraldo","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejpb.2024.114223_b0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejpb.2024.114223_b0150","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nm.3214","article-title":"Acid sphingomyelinase\u2013ceramide system mediates effects of antidepressant drugs","volume":"19","author":"Gulbins","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2024.114223_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023852","article-title":"Identification of novel functional inhibitors of acid sphingomyelinase","volume":"6","author":"Kornhuber","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2024.114223_b0160","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1021\/acsnano.0c00666","article-title":"Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner","volume":"14","author":"Van de Vyver","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2024.114223_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123348","article-title":"Repositioning the antihistamine ebastine as an intracellular siRNA delivery enhancer","volume":"644","author":"Muntean","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114223_b0170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2010.04.012","article-title":"Prolonged gene silencing by combining siRNA nanogels and photochemical internalization","volume":"145","author":"Raemdonck","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0175","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1183\/09031936.05.00095204","article-title":"Time course of cigarette smoke-induced pulmonary inflammation in mice","volume":"26","author":"D\u2019hulst","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2024.114223_b0180","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1185\/030079907X242863","article-title":"Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma","volume":"23","author":"Brookman","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejpb.2024.114223_b0185","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1021\/mp200641e","article-title":"Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction","volume":"9","author":"Funk","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114223_b0190","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/jps.23949","article-title":"Amine-containing molecules and the induction of an expanded lysosomal volume phenotype: a structure-activity relationship study","volume":"103","author":"Logan","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114223_b0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/164_2016_64","article-title":"\u03b22 Agonists","volume":"237","author":"Billington","year":"2016","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114223_b0200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjp.2008.284","article-title":"Novel long-acting bronchodilators for COPD and asthma","volume":"155","author":"Cazzola","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114223_b0205","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1164\/ajrccm.153.2.8564107","article-title":"Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema","volume":"153","author":"Llewellyn-Jones","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejpb.2024.114223_b0210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.apsb.2013.06.005","article-title":"Achieving efficient RNAi therapy: progress and challenges","volume":"3","author":"Gao","year":"2013","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2024.114223_b0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/138920011794520017","article-title":"Improving siRNA bio-distribution and minimizing side effects","volume":"12","author":"Scaggiante","year":"2011","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejpb.2024.114223_b0220","doi-asserted-by":"crossref","first-page":"18355","DOI":"10.1073\/pnas.1214066109","article-title":"Optical tweezers reveal relationship between microstructure and nanoparticle penetration of pulmonary mucus","volume":"109","author":"Kirch","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.ejpb.2024.114223_b0225","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","volume":"532","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114223_b0230","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/mt.2016.182","article-title":"The mucus barrier to inhaled gene therapy","volume":"24","author":"Duncan","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejpb.2024.114223_b0235","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejpb.2015.02.014","article-title":"Barrier or carrier? Pulmonary surfactant and drug delivery","volume":"95","author":"Hidalgo","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114223_b0240","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1021\/mp1002448","article-title":"Surface tension gradient driven spreading on aqueous mucin solutions: a possible route to enhanced pulmonary drug delivery","volume":"8","author":"Koch","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114223_b0245","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","article-title":"PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy","volume":"285","author":"Osman","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114223_b0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery HHS Public Access Graphical abstract","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2024.114223_b0255","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2024.114223_b0260","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1264913","article-title":"The role of macrophages in the pathogenesis of ALI\/ARDS","volume":"2018","author":"Huang","year":"2018","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ejpb.2024.114223_b0265","doi-asserted-by":"crossref","DOI":"10.1038\/mi.2012.74","article-title":"The alveolar macrophages in asthma: a double-edged sword","volume":"5","author":"Balhara","year":"2012","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejpb.2024.114223_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020582","article-title":"Lung macrophage phenotypes and functional responses: Role in the pathogenesis of COPD","volume":"19","author":"Yamasaki","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2024.114223_b0275","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/thoraxjnl-2015-207020","article-title":"Pulmonary macrophages: Key players in the innate defence of the airways","volume":"70","author":"Byrne","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.ejpb.2024.114223_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115144","article-title":"Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano\u2013bio interactions","volume":"203","author":"Zhang","year":"2023","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:42:13Z","timestamp":1738438933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":56,"alternative-id":["S0939641124000493"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114223","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating \u03b22-agonists as siRNA delivery adjuvants for pulmonary surfactant-coated nanogel inhalation therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114223"}}